Strategies for identifying modifier genes in cystic fibrosis

Proceedings of the American Thoracic Society

Volumn 4, Issue 1, 2007, Pages 52-57

  Boyle, Michael P ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cystic fibrosis; Genotype; Modifier; Phenotype; Transforming growth factor

Indexed keywords

ADIPONECTIN; ALPHA 1 ANTITRYPSIN; BETA 2 ADRENERGIC RECEPTOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLUATAMATE CYSTEINE LIGASE; GLUTATHIONE TRANSFERASE; LIGASE; MANNOSE BINDING LECTIN; STATHERIN; TRANSFORMING GROWTH FACTOR BETA; TRANSMEMBRANE CONDUCTANCE REGULATOR; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ALLELE; CODON; CYSTIC FIBROSIS; DISEASE SEVERITY; FORCED EXPIRATORY VOLUME; GENE IDENTIFICATION; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HOMOZYGOSITY; HUMAN; MICROARRAY ANALYSIS; NONHUMAN; PHENOTYPE; PREVALENCE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SOCIAL STATUS;

CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; GENOTYPE; HUMANS; MUTATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHENOTYPE; POLYMORPHISM, GENETIC;

EID: 33846051977     PISSN: 15463222     EISSN: None     Source Type: Journal    
DOI: 10.1513/pats.200605-129JG     Document Type: Review

References (62)

1. Davies JC, Griesenbach U, Alton E. Modifier genes in cystic fibrosis. Pediatr Pulmonol 2005;39:383-391.
2. Knight JC. Regulatory polymorphisms underlying complex disease traits. J Mol Med 2005;83:97-109.
3. Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R, Grzelczak Z, Zielenski J, Lok S, Plavsic N, Chou JL, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989;245:1066-1073.
4. Gadsby DC, Vergani P, Csanady L. The ABC protein turned chloride channel whose failure causes cystic fibrosis. Nature 2006;440:477-483.
5. Cystic Fibrosis Foundation. Patient registry 2005 annual report. Bethesda, MD: Cystic Fibrosis Foundation; 2006.
6. Rowntree RK, Harris A. The phenotypic consequences of CFTR mutations. Ann Hum Genet 2003;67:471-485.
7. Zielenski J, Sang R, Tsui LC. Cystic fibrosis mutation database. The Hospital for Sick Children, Toronto, ON. Available from: http://www. genet.sickkids.on.ca/cftr/StatisticsPage.htm (accessed September 26, 2006).
8. Kerem E, Corey M, Kerem BS, Rommens J, Markiewicz D, Levison H, Tsui LC, Durie P. The relation between genotype and phenotype in cystic fibrosis: analysis of the most common mutation (delta F508). N Engl J Med 1990;323:1517-1522.
9. McKone EF, Emerson SS, Edwards KL, Aitken ML. Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study. Lancet 2003;361:1671-1676.
10. O'Connor GT, Quinton HB, Kahn R, Robichaud P, Maddock J, Lever T, Detzer M, Brooks JG. Case-mix adjustment for evaluation of mortality in cystic fibrosis. Pediatr Pulmonol 2002;33:99-105.
11. Sharma R, Florea VG, Bolger AP, Doehner W, Florea ND, Coats AJS, Hodson ME, Anker SD, Henein MY. Wasting as an independent predictor of mortality in patients with cystic fibrosis. Thorax 2001;56: 746-750.
12. Kovesi T, Corey M, Levison H. Passive smoking and lung function in cystic fibrosis. Am Rev Respir Dis 1993;148:1266-1271.
13. Goss CH, Newsom SA, Schildcrout JS, Sheppard L, Kaufman JD. Effect of ambient air pollution on pulmonary exacerbations and lung function in cystic fibrosis. Am J Respir Crit Care Med 2004;169:816-821.
14. Schechter MS, Shelton BJ, Margolis PA, FitzSimmons SC. The association of socioeconomic status with outcomes in cystic fibrosis patients in the United States. Am J Respir Crit Care Med 2001;163:1331-1337.
15. Jones AM, Dodd ME, Govan JR, Barcus V, Doherty CJ, Morris J, Webb AK. Burkholderia cenocepacia and Burkholderia multivorans: influence on survival in cystic fibrosis. Thorax 2004;59:948-951.
16. Mekus N, Ballmann M, Bronsveld I, Bijman J, Veeze H, Tummler B. Categories of deltaF508 homozygous cystic fibrosis twin and sibling pairs with distinct phenotypic characteristics. Twin Res 2000;3:277-293.
17. Rozmahel R, Wilschanski M, Matin A, Plyte S, Oliver M, Auerbach W, Moore A, Forstner J, Durie P, Nadeau J, et al. Modulation of disease severity in cystic fibrosis transmembrane conductance regulator deficient mice by a secondary genetic factor. Nat Genet 1996;12:280-287.
18. Grubb BR, Boucher RC. Pathophysiology of gene-targeted mouse models for cystic fibrosis. Physiol Rev 1999;79:S193-S214.
19. Kulich M, Rosenfeld M, Campbell J, Kronmal R, Gibson RL, Goss CH, Ramsey B. Disease-specific reference equations for lung function in patients with cystic fibrosis. Am J Respir Crit Care Med 2005;172:885-891.
20. Schluchter MD, Konstan MW, Davis PB. Jointly modelling the relationship between survival and pulmonary function in cystic fibrosis patients. Stat Med 2002;21:1271-1287.
21. Corey M, McLaughlin FJ, Williams M, Levison H. A comparison of survival, growth, and pulmonary function in patients with cystic fibrosis in Boston and Toronto. J Clin Epidemiol 1988;41:583-591.
22. Garred P, Pressler T, Madsen HO, Frederiksen B, Svejgaard A, Hoiby N, Schwartz M, Koch C. Association of mannose-binding lectin gene heterogeneity with severity of lung disease and survival in cystic fibrosis. J Clin Invest 1999;104:431-437.
23. Davies JC, Turner MW, Klein N. Impaired pulmonary status in cystic fibrosis adults with two mutated MBL-2 alleles. Eur Respir J 2004; 24:798-804.
24. Arkwright PD, Laurie S, Super M, Pravica V, Schwarz MJ, Webb AK, Hutchinson IV. TGF-beta(1) genotype and accelerated decline in lung function of patients with cystic fibrosis. Thorax 2000;55:459-462.
25. Matsushita M, Fujita T. Activation of the classical complement pathway by mannose-binding protein in association with a novel C1s-like serine protease. J Exp Med 1992;176:1497-1502.
26. Garred P, Larsen F, Madsen HO, Koch C. Mannose-binding lectin deficiency-revisited. Mol Immunol 2003;40:73-84.
27. Kawamoto M, Romberger DJ, Nakamura Y, Adachi Y, Tate L, Ertl RF, Spurzem JR, Rennard SI. Modulation of fibroblast type I collagen and fibronectin production by bovine bronchial epithelial cells. Am J Respir Cell Mol Biol 1995;12:425-433.
28. Ignotz RA, Massague J. Transforming growth factor-beta stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix. J Biol Chem 1986;261:4337-4345.
29. Howe KL, Wang A, Hunter MM, Stanton BA, McKay DM. TGFbeta down-regulation of the CFTR: a means to limit epithelial chloride secretion. Exp Cell Res 2004;298:473-484.
30. Dunning AM, Ellis PD, McBride S, Kirschenlohr HL, Healey CS, Kemp PR, Luben RN, Chang-Claude J, Mannermaa A, Kataja V, et al. A transforming growth factorbeta1 signal peptide variant increases secretion in vitro and is associated with increased incidence of invasive breast cancer. Cancer Res 2003;63:2610-2615.
31. Grainger DJ, Heathcote K, Chiano M, Snieder H, Kemp PR, Metcalfe JC, Carter ND, Spector TD. Genetic control of the circulating concentration of transforming growth factor type beta1. Hum Mol Genet 1999;8:93-97.
32. Perrey C, Pravica V, Sinnott PJ, Hutchinson IV. Genotyping for polymorphisms in interferon-gamma, interleukin-10, transforming growth factor-beta 1 and tumour necrosis factor-alpha genes: a technical report. Transpl Immunol 1998;6:193-197.
33. Arkwright PD, Pravica V, Geraghty PJ, Super M, Webb AK, Schwarz M, Hutchinson IV. End-organ dysfunction in cystic fibrosis: association with angiotensin I converting enzyme and cytokine gene polymorphisms. Am J Respir Crit Care Med 2003;167:384-389.
34. Frangolias DD, Ruan J, Wilcox PJ, Davidson AG, Wong LT, Berthiaume Y, Hennessey R, Freitag A, Pedder L, Corey M, et al. Alpha 1-antitrypsin deficiency alleles in cystic fibrosis lung disease. Am J Respir Cell Mol Biol 2003;29:390-396.
35. Buscher R, Eilmes KJ, Grasemann H, Torres B, Knauer N, Sroka K, Insel PA, Ratjen F. beta2 adrenoceptor gene polymorphisms in cystic fibrosis lung disease. Pharmacogenetics 2002;12:347-353.
36. Baranov VS, Ivaschenko T, Bakay B, Aseev M, Belotserkovskaya R, Baranova H, Malet P, Perriot J, Mouraire P, Baskakov VN, et al. Proportion of the GSTM1 0/0 genotype in some Slavic populations and its correlation with cystic fibrosis and some multifactorial diseases. Hum Genet 1996;97:516-520.
37. Grasemann H, Storm van's GK, Buscher R, Knauer N, Silverman ES, Palmer LJ, Drazen JM, Ratjen F. Endothelial nitric oxide synthase variants in cystic fibrosis lung disease. Am J Respir Crit Care Med 2003;167:390-394.
38. Hull J, Thomson AH. Contribution of genetic factors other than CFTR to disease severity in cystic fibrosis. Thorax 1998;53:1018-1021.
39. McKone EF, Shao J, Frangolias DD, Keener CL, Shephard CA, Farin FM, Tonelli MR, Pare PD, Sandford AJ, Aitken ML, et al. Variants in the glutamate-cysteine-ligase gene are associated with cystic fibrosis lung disease. Am J Respir Crit Care Med 2006;174:415-419.
40. Long AD, Langley CH. The power of association studies to detect the contribution of candidate genetic loci to variation in complex traits. Genome Res 1999;9:720-731.
41. Drumm ML, Konstan MW, Schluchter MD, Handler A, Pace R, Zou F, Zariwala M, Fargo D, Xu A, Dunn JM, et al. Genetic modifiers of lung disease in cystic fibrosis. N Engl J Med 2005;353:1443-1453.
42. Dorfman R, Sandford AJ, Corey M, Markiewicz D, Yuan X, Master A, Inna E, Sang Y, Lin F, Wang V, et al. Canadian CF Modifier Gene Project: the current status. Pediatr Pulmonol 2005;S28:173.
43. MacGregor AJ, Snieder H, Schork NJ, Spector TD. Twins: novel uses to study complex traits and genetic diseases. Trends Genet 2000;16: 131-134.
44. 1 [abstract]. Proc Am Thorac Soc 2006;3:A408.
45. Stanke F, Becker T, Cuppens H, Kumar V, Cassiman JJ, Jansen S, Radojkovic D, Siebert B, Yarden J, Ussery DW, et al. The TNFalpha receptor TNFRSF1A and genes encoding the amiloride-sensitive sodium channel ENaC as modulators in cystic fibrosis. Hum Genet 2006;119:331-343.
46. Cutting GR. Modifier genetics: cystic fibrosis. Annu Rev Genomics Hum Genet 2005;6:237-260.
47. Burunawuti K, Cheng S, Merlo C, Zeitlin P, Rosenstein B, Mogayzel P, Wang X, Boyle MP, Cutting GR. Variants in the mannose binding lectin gene modify survival of cystic fibrosis patients. Pediatr Pulmonol 2003;S25:215.
48. Carlsson M, Sjoholm AG, Eriksson L, Thiel S, Jensenius JC, Segelmark M, Truedsson L. Deficiency of the mannan-binding lectin pathway of complement and poor outcome in cystic fibrosis: bacterial colonization may be decisive for a relationship. Clin Exp Immunol 2005;139:306-313.
49. Wright JM, Merlo CA, Reynolds JB, Zeitlin PL, Garcia JG, Guggino WB, Boyle MP. Respiratory epithelial gene expression in cystic fibrosis patients with mild and severe lung disease. Am J Respir Cell Mol Biol 2006;35:327-336.
50. Kochanska B, Kedzia A, Kamysz W, Mackiewicz Z, Kupryszewski G. The effect of statherin and its shortened analogues on anaerobic bacteria isolated from the oral cavity. Acta Microbiol Pol 2000;49:243-251.
51. Proctor GB, Hamdan S, Carpenter GH, Wilde P. Astatherin and calcium enriched layer at the air interface of human parotid saliva. Biochem J 2005;389:111-116.
52. Wolf AM, Wolf D, Rumpold H, Enrich B, Tilg H. Adiponectin induces the anti-inflammatory cytokines IL-10 and IL-1RA in human leukocytes. Biochem Biophys Res Commun 2004;323:630-635.
53. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, Yamashita S, Noda M, Kita S, Ueki K, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002;8:1288-1295.
54. Vasseur F, Helbecque N, Lobbens S, Vasseur-Delannoy V, Dina C, Clement K, Boutin P, Kadowaki T, Scherer PE, Froguel P. Hypoadiponectinaemia and high risk of type 2 diabetes are associated with adiponectin-encoding (ACDC) gene promoter variants in morbid obesity: evidence for a role of ACDC in diabesity. Diabetologia 2005;48:892-899.
55. Yao T, Cohen RE. Cyclization of polyubiquitin by the E2-25K ubiquitin conjugating enzyme. J Biol Chem 2000;275:36862-36868.
56. Gunderson KL, Kuhn KM, Steemers FJ, Ng P, Murray SS, Shen R. Whole-genome genotyping of haplotype tag single nucleotide polymorphisms. Pharmacogenomics 2006;7:641-648.
57. Thompson D, Stram D, Goldgar D, Witte JS. Haplotype tagging single nucleotide polymorphisms and association studies. Hum Hered 2003; 56:48-55.
58. Howie BN, Carlson CS, Rieder MJ, Nickerson DA. Efficient selection of tagging single-nucleotide polymorphisms in multiple populations. Hum Genet 2006;120:58-68.
59. Hirschhorn JN. Genetic approaches to studying common diseases and complex traits. Pediatr Res 2005;57:74R-77R.
60. Wang H, Thomas DC, Itsik P, Stram DO. Optimal two-stage genotyping designs for genome-wide association scans. Genet Epidemiol 2006; 30:356-368.
61. Hirschhorn JN, Daly MJ. Genome-wide association studies for common diseases and complex traits. Nat Rev Genet 2005;6:95-108.
62. McKone EF, Rodgers CE, Genatossio A, McNamara S, Gibson RL, Aitken ML. Candidate pathway approach to identifying genetic modifiers in cystic fibrosis. Pediatr Pulmonol 2005;S28:185.